• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

停止毒液免疫治疗后的长期保护作用:200例患者再次被蜇伤的结果

Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients.

作者信息

Lerch E, Müller U R

机构信息

Division of Internal Medicine, Zieglerspital, Bern, Switzerland.

出版信息

J Allergy Clin Immunol. 1998 May;101(5):606-12. doi: 10.1016/S0091-6749(98)70167-8.

DOI:10.1016/S0091-6749(98)70167-8
PMID:9600496
Abstract

BACKGROUND

Venom immunotherapy (VIT) protects most patients allergic to Hymenoptera stings while booster injections are continued. Few data on long-term protection after discontinuation of treatment are available.

OBJECTIVE

We sought to investigate protection from re-stings over a prolonged period after stopping VIT.

METHODS

Re-sting data were obtained from 200 of 322 patients in whom VIT had been stopped between 1988 and 1992 after a duration of at least 3 years. The 25 (12.5%) patients who again developed systemic allergic reactions were compared with 50 matched patients without re-sting reactions. Clinical data and diagnostic parameters (i.e., skin sensitivity and specific IgE and IgG) were studied.

RESULTS

Of the 25 patients who had re-sting reactions, 19 had been treated with bee venom (relapse rate, 15.8%), and six had been treated with Vespula venom (relapse rate, 7.5%). About half of the re-sting reactions occurred on the first resting after stopping VIT. Most of these reactions were mild, whereas the majority of reactions occurring after repeated re-stings were severe. When re-sting reactions were related to the total re-stings per year, an accumulation of sting reactions was observed in years 3 to 5 after stopping VIT. Patients with re-sting reactions had been receiving VIT for a significantly shorter duration (43.35 months) than those with continued protection (54.65 months) (p < 0.01). Of the diagnostic parameters, only a negative intracutaneous skin test at 10(-3) gm/L predicted long-term protection reliably.

CONCLUSION

Venom immunotherapy of 3 to 5 years duration induces long-term protection in most patients. In rare occasions severe re-sting reactions may, however, occur, especially after repeated re-stings.

摘要

背景

毒液免疫疗法(VIT)在持续进行加强注射时可保护大多数对膜翅目昆虫叮咬过敏的患者。关于停止治疗后的长期保护的数据很少。

目的

我们试图研究停止VIT后长时间内免受再次叮咬的保护情况。

方法

从1988年至1992年期间停止VIT且疗程至少为3年的322例患者中的200例获取再次叮咬数据。将再次发生全身过敏反应的25例(12.5%)患者与50例匹配的无再次叮咬反应的患者进行比较。研究临床数据和诊断参数(即皮肤敏感性以及特异性IgE和IgG)。

结果

在有再次叮咬反应的25例患者中,19例接受过蜂毒治疗(复发率15.8%),6例接受过黄蜂毒液治疗(复发率7.5%)。约一半的再次叮咬反应发生在停止VIT后的首次叮咬时。这些反应大多为轻度,而在多次再次叮咬后发生的反应多数为重度。当再次叮咬反应与每年的总叮咬次数相关时,在停止VIT后的第3至5年观察到叮咬反应的累积。有再次叮咬反应的患者接受VIT的疗程(43.35个月)明显短于有持续保护的患者(54.65个月)(p<0.01)。在诊断参数中,仅10(-3)g/L时的阴性皮内皮肤试验能可靠地预测长期保护。

结论

持续3至5年的毒液免疫疗法可使大多数患者获得长期保护。然而,在极少数情况下可能会发生严重的再次叮咬反应,尤其是在多次再次叮咬后。

相似文献

1
Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients.停止毒液免疫治疗后的长期保护作用:200例患者再次被蜇伤的结果
J Allergy Clin Immunol. 1998 May;101(5):606-12. doi: 10.1016/S0091-6749(98)70167-8.
2
Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.在接受常规膜翅目毒液免疫治疗时仍对叮咬激发试验有反应的患者,通过增加毒液剂量得到保护。
J Allergy Clin Immunol. 2001 Dec;108(6):1027-32. doi: 10.1067/mai.2001.119154.
3
Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.对膜翅目昆虫毒液过敏患者在免疫治疗前及治疗期间的免疫印迹研究。
Eur Ann Allergy Clin Immunol. 2005 Sep;37(7):273-8.
4
Discontinuing venom immunotherapy: extended observations.停止毒液免疫疗法:长期观察
J Allergy Clin Immunol. 1998 Mar;101(3):298-305. doi: 10.1016/S0091-6749(98)70239-8.
5
Long-term efficacy of venom immunotherapy.毒液免疫疗法的长期疗效。
Ann Allergy Asthma Immunol. 2008 Feb;100(2):162-5. doi: 10.1016/S1081-1206(10)60425-5.
6
Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.每3个月进行一次的维持性毒液免疫疗法既安全又有效。
J Allergy Clin Immunol. 2001 May;107(5):902-6. doi: 10.1067/mai.2001.114986.
7
Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.农村地区昆虫毒液过敏患者进行毒液免疫治疗的疗效调查
J Dtsch Dermatol Ges. 2008 Apr;6(4):292-7. doi: 10.1111/j.1610-0387.2007.06579.x. Epub 2007 Nov 27.
8
Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy.基础肥大细胞类胰蛋白酶血清浓度:在长期免疫治疗蜂毒过敏中的下降证据。
Clin Exp Allergy. 2010 Apr;40(4):643-9. doi: 10.1111/j.1365-2222.2009.03436.x. Epub 2010 Jan 20.
9
Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice.膜翅目昆虫毒液过敏的预防与治疗:临床实践指南
Allergy. 2005 Dec;60(12):1459-70. doi: 10.1111/j.1398-9995.2005.00960.x.
10
The value of immunotherapy with venom in children with allergy to insect stings.昆虫叮咬过敏儿童使用毒液免疫疗法的价值。
N Engl J Med. 1990 Dec 6;323(23):1601-3. doi: 10.1056/NEJM199012063232305.

引用本文的文献

1
Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy.犬类的膜翅目毒液免疫疗法:安全性与临床疗效
Animals (Basel). 2023 Sep 23;13(19):3002. doi: 10.3390/ani13193002.
2
Diagnosis and Management of Insect Allergy: Barriers and Facilitators in the United States.昆虫过敏的诊断与管理:美国的障碍与促进因素
J Asthma Allergy. 2022 Dec 15;15:1773-1781. doi: 10.2147/JAA.S364867. eCollection 2022.
3
Role of Respiratory Epithelial Cells in Allergic Diseases.呼吸道上皮细胞在过敏性疾病中的作用。
Cells. 2022 Apr 20;11(9):1387. doi: 10.3390/cells11091387.
4
Intralymphatic Immunotherapy (ILIT) With Bee Venom Allergens: A Clinical Proof-of-Concept Study and the Very First ILIT in Humans.蜂毒变应原的淋巴内免疫疗法(ILIT):一项临床概念验证研究及首例人体ILIT。
Front Allergy. 2022 Mar 16;3:832010. doi: 10.3389/falgy.2022.832010. eCollection 2022.
5
Association between Venom Immunotherapy and Changes in Serum Protein-Peptide Patterns.毒液免疫疗法与血清蛋白质-肽谱变化之间的关联。
Vaccines (Basel). 2021 Mar 12;9(3):249. doi: 10.3390/vaccines9030249.
6
Long-term impact of hymenoptera venom immunotherapy on clinical course, immune parameters, and psychosocial aspects.膜翅目昆虫毒液免疫疗法对临床病程、免疫参数及社会心理方面的长期影响。
Allergol Select. 2021 Jan 26;5:57-66. doi: 10.5414/ALX02175E. eCollection 2021.
7
Benefits and limitations of sting challenge in hymenoptera venom allergy.膜翅目毒液过敏中刺蛰激发试验的益处与局限性
Allergol Select. 2021 Jan 18;5:45-50. doi: 10.5414/ALX02148E. eCollection 2021.
8
Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes.膜翅目毒液过敏的精准医学:不同表型和内型的诊断、生物标志物和治疗。
Front Immunol. 2020 Oct 22;11:579409. doi: 10.3389/fimmu.2020.579409. eCollection 2020.
9
EAACI Allergen Immunotherapy User's Guide.EAACI 过敏原免疫治疗用户指南。
Pediatr Allergy Immunol. 2020 May;31 Suppl 25(Suppl 25):1-101. doi: 10.1111/pai.13189.
10
Clinical Utility of Rush Venom Immunotherapy: Current Status.速发型毒液免疫疗法的临床应用:现状
J Asthma Allergy. 2020 Jan 7;13:1-10. doi: 10.2147/JAA.S200917. eCollection 2020.